Search research articles
Contact Us
Filters
Showing results (521-530 of 539) with videos related to
Page
of 54
Sort By:
ACS Combinatorial Science
|
November 13, 2015
Cell-Based Selection Expands the Utility of DNA-Encoded Small-Molecule Library Technology to Cell Surface Drug Targets: Identification of Novel Antagonists of the NK3 Tachykinin Receptor
Zining Wu, Todd L Graybill, Xin Zeng, et al.
Cancer
|
April 15, 2023
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Mansoor R Mirza, Antonio González-Martín, Whitney S Graybill, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 5, 2006
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial
Thomas J Walsh, Issam Raad, Thomas F Patterson, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
June 29, 2023
Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial
Connie N Hess, Judith Hsia, Ian A Carroll, et al.
Breast Cancer Research and Treatment
|
October 18, 2024
Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer
Isaac Garcia-Murillas, Rosalind J Cutts, Giselle Walsh-Crestani, et al.
Clinical Therapeutics
|
July 17, 2024
Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer
Bradley J Monk, Ignacio Romero, Whitney Graybill, et al.
Journal of Comparative Effectiveness Research
|
December 6, 2024
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
Whitney S Graybill, Ignace Vergote, Bhavana Pothuri, et al.
The New England Journal of Medicine
|
September 29, 2019
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2024
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
B J Monk, M P Barretina-Ginesta, B Pothuri, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 4, 2023
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer
Robert W Holloway, Premal Thaker, Alberto A Mendivil, et al.
Page
of 54
Search research articles
Search
Showing results (521-530 of 539) with videos related to
Sort By:
Page
of 54
ACS Combinatorial Science
|
November 13, 2015
Cell-Based Selection Expands the Utility of DNA-Encoded Small-Molecule Library Technology to Cell Surface Drug Targets: Identification of Novel Antagonists of the NK3 Tachykinin Receptor
Zining Wu, Todd L Graybill, Xin Zeng, et al.
Cancer
|
April 15, 2023
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Mansoor R Mirza, Antonio González-Martín, Whitney S Graybill, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 5, 2006
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial
Thomas J Walsh, Issam Raad, Thomas F Patterson, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
June 29, 2023
Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial
Connie N Hess, Judith Hsia, Ian A Carroll, et al.
Breast Cancer Research and Treatment
|
October 18, 2024
Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer
Isaac Garcia-Murillas, Rosalind J Cutts, Giselle Walsh-Crestani, et al.
Clinical Therapeutics
|
July 17, 2024
Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer
Bradley J Monk, Ignacio Romero, Whitney Graybill, et al.
Journal of Comparative Effectiveness Research
|
December 6, 2024
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
Whitney S Graybill, Ignace Vergote, Bhavana Pothuri, et al.
The New England Journal of Medicine
|
September 29, 2019
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2024
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
B J Monk, M P Barretina-Ginesta, B Pothuri, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 4, 2023
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer
Robert W Holloway, Premal Thaker, Alberto A Mendivil, et al.
Page
of 54